Chemistry:Insulin tregopil
From HandWiki
| Clinical data | |
|---|---|
| Other names | IN-105 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
Insulin tregopil is a fast-acting insulin analog, unlike other forms of insulin it is delivered by mouth. It is developed by Biocon for diabetes.[1][2][3][4][5]
References
- ↑ Joshi, Shashank; Jayanth, Vathsala; Loganathan, Subramanian; Sambandamurthy, Vasan K.; Athalye, Sandeep N. (September 2023). "Insulin Tregopil: An Ultra-Fast Oral Recombinant Human Insulin Analog: Preclinical and Clinical Development in Diabetes Mellitus". Drugs 83 (13): 1161–1178. doi:10.1007/s40265-023-01925-1. PMID 37578592.
- ↑ Khedkar, Anand; Lebovitz, Harold; Fleming, Alexander; Cherrington, Alan; Jose, Vinu; Athalye, Sandeep N.; Vishweswaramurthy, Ashwini (May 2019). "Impact of Insulin Tregopil and Its Permeation Enhancer on Pharmacokinetics of Metformin in Healthy Volunteers: Randomized, Open-Label, Placebo-Controlled, Crossover Study". Clinical and Translational Science 12 (3): 276–282. doi:10.1111/cts.12609. PMID 30592549.
- ↑ Khedkar, Anand P.; Jose, Vinu; Lebovitz, Harold E.; Cherrington, Alan D.; Fleming, Gilbert Alexander; Athalye, Sandeep N.; Vishweswaramurthy, Ashwini (1 July 2018). "Dosing Time of Insulin Tregopil, a Novel Oral Insulin, in Type 2 Diabetes Mellitus Patients and Its Pharmacodynamic Effect". Diabetes 67 (Supplement_1). doi:10.2337/db18-979-P.
- ↑ Khedkar, Anand; Lebovitz, Harold; Fleming, Alexander; Cherrington, Alan; Jose, Vinu; Athalye, Sandeep N.; Vishweswaramurthy, Ashwini (January 2020). "Pharmacokinetics and Pharmacodynamics of Insulin Tregopil in Relation to Premeal Dosing Time, Between Meal Interval, and Meal Composition in Patients With Type 2 Diabetes Mellitus". Clinical Pharmacology in Drug Development 9 (1): 74–86. doi:10.1002/cpdd.730. PMID 31392840.
- ↑ Lebovitz, Harold E; Fleming, Alexander; Cherrington, Alan D; Joshi, Shashank; Athalye, Sandeep N; Loganathan, Subramanian; Vishweswaramurthy, Ashwini; Panda, Jayanti et al. (2 November 2022). "Efficacy and safety of Tregopil, a novel, ultra-rapid acting oral prandial insulin analog, as part of a basal-bolus regimen in type 2 diabetes: a randomized, active-controlled phase 2/3 study". Expert Opinion on Pharmacotherapy 23 (16): 1855–1863. doi:10.1080/14656566.2022.2141569. PMID 36352762.
 |  |
